Brooks Laboratories, a company in the Pharmaceuticals industry, reported revenue of ₹19 crore and net profit of ₹70 crore for the September 2026 quarter.
Brooks Laboratories (NSE: BROOKS) closed at ₹67.20 on 20 Nov 2026. Its market capitalisation is ₹198 crore and it trades at 68.5 times earnings.
Incorporated in 2002, Brooks Laboratories Ltd is a pharmaceutical company working on contract basis catering to the critical care segment
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.